Covid 19 Research using Clinical Trials (Home Page)
Report for D006973: Hypertension NIH
(Synonyms: Hyperten, Hypertensi, Hypertensio, Hypertension)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (11)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1010 | Sampling salivary Wiki | 0.38 |
| drug279 | Clinical data Wiki | 0.38 |
| drug66 | Angiotensin receptor blocker Wiki | 0.38 |
| drug1145 | The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: Wiki | 0.38 |
| drug1155 | Thiazide or Thiazide-like diuretics Wiki | 0.38 |
| drug308 | Convalescent COVID 19 Plasma Wiki | 0.38 |
| drug236 | Calcium Channel Blockers Wiki | 0.38 |
| drug170 | Blood collection on admission and longitudinally Wiki | 0.38 |
| drug171 | Blood collection on their first consultation and 10 to 14 days later Wiki | 0.38 |
| drug25 | ACE inhibitor Wiki | 0.27 |
| drug309 | Convalescent Plasma Wiki | 0.11 |
Correlated MeSH Terms (13)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001997 | Bronchopulmonary Dysplasia NIH | 0.38 |
| D008595 | Menorrhagia NIH | 0.38 |
| D006470 | Hemorrhage NIH | 0.38 |
| D006929 | Hyperaldosteronism NIH | 0.38 |
| D014552 | Urinary Tract Infections NIH | 0.38 |
| D000309 | Adrenal Insufficiency NIH | 0.38 |
| D054559 | Hyperphosphatemia NIH | 0.38 |
| D007008 | Hypokalemia NIH | 0.38 |
| D002318 | Cardiovascular Diseases NIH | 0.20 |
| D003141 | Communicable Diseases NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| D007239 | Infection NIH | 0.03 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
Correlated HPO Terms (7)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0000822 | Hypertension HPO | 1.00 |
| HP:0000132 | Menorrhagia HPO | 0.38 |
| HP:0002905 | Hyperphosphatemia HPO | 0.38 |
| HP:0002900 | Hypokalemia HPO | 0.38 |
| HP:0000846 | Adrenal insufficiency HPO | 0.38 |
| HP:0000859 | Hyperaldosteronism HPO | 0.38 |
| HP:0001626 | Abnormality of the cardiovascular system HPO | 0.20 |
There are 7 clinical trials
Clinical Trials
1 Prognostic Characteristics Difference Between the Hypertension Patients With and Without ACEI Treatment When Suffered With 2019-nCoV Infection in China
There are currently no clinical studies reporting clinical characteristics difference between the hypertension patients with and without ACEI treatment when suffered with novel coronavirus infection in China.
NCT04272710 2019-nCoV MeSH:Hypertension
HPO:Hypertension
Primary Outcomes
Description: The percentage of patients admitted to the ICU at any time during the 28 days of onset COVID-19.
Measure: Occupancy rate in the intensive care unit (ICU) Time: up to 28 days
Description: The number of patients requiring mechanical ventilation.
Measure: Mechanical Ventilation Time: up to 28 days
Description: The number of patients who died of 2019-nCoV infection.
Measure: Death Time: up to 28 days
Secondary Outcomes
Description: The number of died 2019-nCoV infected patients from any cause.
Measure: All cause mortality Time: up to 28 days
Description: Time from onset of symptoms to admitted to the ICU, requiring mechanical ventilation, and death.
Measure: Time from onset of symptoms to main outcome and its components Time: up to 28 days
Description: Time to Clinical Recovery
Measure: Time to Clinical Recovery Time: up to 28 days
2 Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs
Primary Outcomes
Description: The percentage of patients admitted to the ICU at any time during the 28 days of onset COVID-19.
Measure: Occupancy rate in the intensive care unit (ICU) Time: up to 28 daysDescription: The number of patients requiring mechanical ventilation.
Measure: Mechanical Ventilation Time: up to 28 daysDescription: The number of patients who died of 2019-nCoV infection.
Measure: Death Time: up to 28 daysSecondary Outcomes
Description: The number of died 2019-nCoV infected patients from any cause.
Measure: All cause mortality Time: up to 28 daysDescription: Time from onset of symptoms to admitted to the ICU, requiring mechanical ventilation, and death.
Measure: Time from onset of symptoms to main outcome and its components Time: up to 28 daysDescription: Time to Clinical Recovery
Measure: Time to Clinical Recovery Time: up to 28 daysThe study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
NCT04278404 Coronavirus Infection (COVID-19) Pulmonary Arterial Hypertension Urinary Tract Infections in Children Hypertension Pain Hyperphosphatemia Primary Hyperaldosteronism Edema Hypokalemia Heart Failure Hemophilia Prior to Tooth Extraction Menorrhagia Insomnia Pneumonia Skin Infection Arrythmia Asthma in Children Bronchopulmonary Dysplasia Adrenal Insufficiency Hypertension, Resistant to Conventional Therapy Fibrinolysis; Hemorrhage Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: MeSH:Infection Communicable Diseases Urinary Tract Infections Coronavirus Infections Severe Acute Respiratory Syndrome Bronchopulmonary Dysplasia Menorrhagia Hypertension Hyperphosphatemia Hypokalemia Adrenal Insufficiency Hyperaldosteronism Hemorrhage
HPO:Adrenal insufficiency Hyperaldosteronism Hyperphosphatemia Hypertension Hypokalemia Menorrhagia Primary hyperaldosteronism
Primary Outcomes
Measure: Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: Elimination rate constant (ke) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: Half-life (t1/2) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: Absorption rate constant (ka) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: AUC (area under the curve) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: Maximum concentration (Cmax) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: Time to achieve maximum concentration (Tmax) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
3 Hypertension in Patients Hospitalized With COVID-19 in Wuhan, China: A Single-center Retrospective Observational Study
Primary Outcomes
Measure: Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.Measure: Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: Elimination rate constant (ke) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: Half-life (t1/2) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: Absorption rate constant (ka) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: AUC (area under the curve) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: Maximum concentration (Cmax) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: Time to achieve maximum concentration (Tmax) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Some studies have shown that the main pathogenesis of patients with covid19 is related to ACE2 receptor. Lung is one of the main organs, and there are many ACE2 receptors in cardiovascular system. ACEI / ARB is the main target of antihypertensive drugs. Previous reports suggested that there were large number of patients with covid19 also suffered from hypertension, suggesting that patients with hypertension may be the susceptible to covid19. Therefore, we try to follow up the patients admitted to Hankou hospital to explore the impact of hypertension and hypertension treatment on the severity and prognosis of patients with covid19, so as to provide new methods for the treatment of patients with covid19 in the future.
NCT04318301 COVID-19 Hypertension MeSH:Hypertension
HPO:Hypertension
Primary Outcomes
Description: mortality in 28-day
Measure: Rate of Death Time: From date of admission until the date of death from any cause, up to 60 days
Secondary Outcomes
Description: evaluate the severity of pneumonia according to CT scans and clinical manifestation
Measure: the severity of pneumonia Time: From date of admission until the date of discharge or death from any cause, up to 60 days
Other Outcomes
Description: days from admission to discharge or death
Measure: the length of hospital stay Time: From date of admission until the date of discharge or death from any cause, up to 60 days
4 The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial
Primary Outcomes
Description: mortality in 28-day
Measure: Rate of Death Time: From date of admission until the date of death from any cause, up to 60 daysSecondary Outcomes
Description: evaluate the severity of pneumonia according to CT scans and clinical manifestation
Measure: the severity of pneumonia Time: From date of admission until the date of discharge or death from any cause, up to 60 daysOther Outcomes
Description: days from admission to discharge or death
Measure: the length of hospital stay Time: From date of admission until the date of discharge or death from any cause, up to 60 daysCoronavirus disease 2019 (COVID-19) is a pandemic infection caused by a virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Because SARS-CoV-2 is known to require the angiotensin-converting enzyme 2 (ACE-2) receptor for uptake into the human body, there have been questions about whether medications that upregulate ACE-2 receptors might increase the risk of infection and subsequent complications. One such group of medications are anti-hypertensives that block the renin-angiotensin system, including both angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB). Both ACEi and ARB are widely used for the treatment of hypertension. Early reports from China and Italy suggest that many of those who die from COVID-19 have a coexisting history of hypertension. Consequently, there have been questions raised as to whether these 2 types of blood pressure medication might increase the risk of death among patients with COVID-19. However, it is well known that the prevalence of hypertension increases linearly with age. Therefore, it is possible that the high prevalence of hypertension and ACEi/ARB use among persons who die from COVID-19 is simply confounded by age (older people are at risk of both a history of hypertension and dying from COVID-19). Whether these commonly prescribed blood pressure medications increase the risk of COVID-19 or not remains unanswered. Statements from professional cardiology societies on both sides of the Atlantic have called for urgent research into this question. Our study aims to randomize patients with primary (essential) hypertension who are already taking ACEi/ARB to either switch to an alternative BP medication or continue with the ACEi/ARB that they have already been prescribed. Adults with compelling indications for ACEi/ARB will not be enrolled.
NCT04330300 Hypertension COVID-19 Drug: Thiazide or Thiazide-like diuretics Drug: Calcium Channel Blockers Drug: ACE inhibitor Drug: Angiotensin receptor blocker MeSH:Coronavirus Infections Hypertension
HPO:Hypertension
Primary Outcomes
Description: Time from randomization to the first occurrence of any of the clinical events above
Measure: Number of Covid-19 positive participants who die, require intubation in ICU, or require hospitalization for non-invasive ventilation (NIV) Time: 12 months
Secondary Outcomes
Description: Time from randomization to the first occurrence of above
Measure: Number of Covid-19 positive participants who die Time: 12 months
Description: Time from randomization to the first occurrence of above
Measure: Number of Covid-19 positive participants who require intubation in intensive care unit (ICU) Time: 12 months
Description: Time from randomization to the first occurrence of above
Measure: Number of Covid-19 positive participants who require hospitalization for non-invasive ventilation (NIV) Time: 12 months
Description: Time from randomization to the first occurrence of above
Measure: Number of SARS-CoV-2 positive participants Time: 12 months
Measure: Maximum troponin T value (ng/L) among Covid-19 positive participants who require acute hospitalization Time: 12 months
Description: Performed in a random sub-sample of the cohort (both study arms)
Measure: 24 hour mean systolic BP (mmHg) on ambulatory BP monitoring Time: 12 months
Description: Time from randomization to the first occurrence of above
Measure: All-cause mortality Time: 12 months
5 Phase IV Observational Study to Associate Hypertension and Hypertensinon Treatment to COVID19
Primary Outcomes
Description: Time from randomization to the first occurrence of any of the clinical events above
Measure: Number of Covid-19 positive participants who die, require intubation in ICU, or require hospitalization for non-invasive ventilation (NIV) Time: 12 monthsSecondary Outcomes
Description: Time from randomization to the first occurrence of above
Measure: Number of Covid-19 positive participants who die Time: 12 monthsDescription: Time from randomization to the first occurrence of above
Measure: Number of Covid-19 positive participants who require intubation in intensive care unit (ICU) Time: 12 monthsDescription: Time from randomization to the first occurrence of above
Measure: Number of Covid-19 positive participants who require hospitalization for non-invasive ventilation (NIV) Time: 12 monthsDescription: Time from randomization to the first occurrence of above
Measure: Number of SARS-CoV-2 positive participants Time: 12 monthsMeasure: Maximum troponin T value (ng/L) among Covid-19 positive participants who require acute hospitalization Time: 12 months
Description: Performed in a random sub-sample of the cohort (both study arms)
Measure: 24 hour mean systolic BP (mmHg) on ambulatory BP monitoring Time: 12 monthsDescription: Time from randomization to the first occurrence of above
Measure: All-cause mortality Time: 12 monthsMulticentric non-profit observational study, in patients with COVID-19 hospitalized in Italy, conducted through a pseudonymised survey.
NCT04331574 COVID-19 Hypertension Cardiovascular Diseases MeSH:Hypertension Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system Hypertension
Primary Outcomes
Description: Using anamnestic data collected from the health record of the hospital or of the general practitioner, we will count the number of COVID-19 patients enrolled that were treated with ACE Inhibitors or ARB.
Measure: Numbers of COVID-19 patients enrolled that use ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents Time: 3 months
Description: This study want to observe whether the assumption of antihypertensive ACE inhibitors or ARB increases the severity of the clinical manifestation of COVID19
Measure: Numbers of COVID-19 patients enrolled with no symptoms, with moderate symptoms or with severe symptoms of pneumoni based on the WHO specification for ARDS that also used ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents Time: 3 months
Secondary Outcomes
Description: Collecting selected data from the health record and hospital charts of the patients we will assess whether among the recorded parameters there are any that can predict COVID19 prevalence and severity
Measure: Number and type of anthropometric and clinical parameters that associate with COVID19 and COVID-19 severity Time: 3 months
6 Prospective Monitoring of Drug Safety and the Occurrence of Complications During Hospitalization in Patients With Cardiovascular Diseases With COVID-19
Primary Outcomes
Description: Using anamnestic data collected from the health record of the hospital or of the general practitioner, we will count the number of COVID-19 patients enrolled that were treated with ACE Inhibitors or ARB.
Measure: Numbers of COVID-19 patients enrolled that use ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents Time: 3 monthsDescription: This study want to observe whether the assumption of antihypertensive ACE inhibitors or ARB increases the severity of the clinical manifestation of COVID19
Measure: Numbers of COVID-19 patients enrolled with no symptoms, with moderate symptoms or with severe symptoms of pneumoni based on the WHO specification for ARDS that also used ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents Time: 3 monthsSecondary Outcomes
Description: Collecting selected data from the health record and hospital charts of the patients we will assess whether among the recorded parameters there are any that can predict COVID19 prevalence and severity
Measure: Number and type of anthropometric and clinical parameters that associate with COVID19 and COVID-19 severity Time: 3 monthsHospitalized patients with COVID-19 will be included in the study in centers around Poland. After the hospitalization, a short questionnaire will be completed, including pre-hospitalization diagnoses, pre-hospitalization medications, clinical status on admission, the course, complication and the duration of hospitalization. The questionnaire will be available in paper form and on-line.
NCT04374110 COVID Hypertension Cardiovascular Diseases Cardiovascular Risk Factor Other: Clinical data MeSH:Hypertension Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system Hypertension
Primary Outcomes
Description: Death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke
Measure: Adverse events Time: through study completion, an average of 2 weeks
Secondary Outcomes
Description: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke analyzed separately for each of the endpoints
Measure: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke Time: through study completion, an average of 2 weeks
Description: Ventilation during hospitalization
Measure: Ventilation during hospitalization Time: through study completion, an average of 2 weeks
Description: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke analyzed separately for each of the endpoints
Measure: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke Time: prolonged follow up, through study completion, an average of one year
7 Association Between Hypertension, Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19
Primary Outcomes
Description: Death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke
Measure: Adverse events Time: through study completion, an average of 2 weeksSecondary Outcomes
Description: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke analyzed separately for each of the endpoints
Measure: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke Time: through study completion, an average of 2 weeksDescription: Ventilation during hospitalization
Measure: Ventilation during hospitalization Time: through study completion, an average of 2 weeksDescription: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke analyzed separately for each of the endpoints
Measure: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke Time: prolonged follow up, through study completion, an average of one yearBackground. Angiotensing converting enzyme type 2 (ACE2), a key enzyme of the renin-angiotensin-aldosterone system (RAAS), is the receptor of SARS-CoV-2 for cell entry into lungs. Because ACE2 may be modulated by RAAS inhibitors, such as angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARBs), there is concern that patients treated with ACEi and ARBs may be at higher risk for COVID-19 infection and severity. Aim. To analyze the associations between COVID-19 and hypertension, and treatments with ACEi and ARBs. Methods. In this retrospective observational study, consecutive patients hospitalized for suspected COVID-19 pneumonia will be divided into 2 groups, whether or not COVID-19 is confirmed. The two groups will be compared for baseline characteristics, mainly prior treatment with ACEi and ARBs, and clinical outcome at 1-month follow-up. The main hypothesis is that ACEi and ARBs, which interact differently with ACE2, may have different relationships with COVID-19 infection or severity.
NCT04374695 COVID-19 MeSH:Hypertension
HPO:Hypertension
Primary Outcomes
Description: Prevalence of a previous treatment by angiotensin converting enzyme inhibitors in patients with and without confirmed Covid-19 pneumonia.
Measure: Prior treatment by ACEi Time: at admission to hospital
Description: Prevalence of a previous treatment by angiotensin II type 1-receptor blockers in patients with and without confirmed Covid-19 pneumonia.
Measure: Prior treatment by ARB Time: at admission to hospital
Secondary Outcomes
Description: Association between COVID-19 infection status and other baseline characteristics and comorbidities (age, sex, history of hypertension, chronic heart disease, diabetes mellitus, COPD, asthma, obesity, allergies)
Measure: Baseline characteristics and comorbidities Time: at admission to hospital
Description: Association between previous treatment by ACEi and ARBs and clinical course of COVID-19 (one-month mortality, hospitalization in intensive care unit, duration of hospital stay, early discharge to home)
Measure: Major Clinical Adverse Events Time: One month follow-up
HPO Nodes
HP:0000822: Hypertension
Genes 418
PDE11A WT1 BBS10 TGFB2 COL1A1 KCTD1 MLX ND5 SCNN1A GPR101 TRNS2 B2M CFI NOTCH3 ALX4 TNFRSF11A GATA5 EXT2 LYZ MUC1 ERCC6 TRNL1 STOX1 COX3 PRKACA MTTP BSCL2 TRNS1 PKD2 KRT8 TRNL1 SLC2A10 CDH23 LEMD3 WT1 TBX1 TRIM28 KCTD1 ND1 CYTB WNK1 ELP1 WDR19 AIP COX2 LOX TGFBR2 GCH1 KRT18 SCNN1B CORIN UFD1 CFH SCNN1G HGD PDE11A COL4A4 BRCA2 NR3C1 CACNA1D LMNA FBN1 ND1 TRNQ VHL JMJD1C CBS RPGRIP1L TGFBR3 POR SDHD TRNS1 ALMS1 CACNA1H TSC1 LRP6 CD2AP FBN1 COX2 DYRK1B SEC24C ADA2 HPSE2 NF1 LDLRAP1 HLA-DRB1 WNK4 ACVRL1 CCND1 FBN1 VHL GLA PDE3A ABCG8 SH2B3 MMP2 SLC52A2 ARMC5 SLC25A11 ERCC4 BBIP1 PAM16 HLA-DPA1 PDE8B ACAT1 LMNA GLA GUCY1A1 MAFB DIS3L2 COL5A2 NKX2-5 CYP11B1 TRNL1 BBS1 FGFR2 LEMD3 MYH7 PPARG FLT1 FN1 COMT MYMK MTRR FOXF1 FN1 CFB MKKS SDHD CYP11B1 MGP SDCCAG8 GJA1 SH2B3 CYP17A1 SUGCT TGFB3 COX1 ANGPTL6 ELN ACTN4 REST HMBS HSD11B2 ND5 SDHD SMAD4 ND4 KCNJ5 LRIG2 NPHP1 TRNQ FMO3 HMBS PTPN22 FGFR2 GBA ELN KIF1B SDHB SLC2A10 COX1 ENG RREB1 CCR6 CYP11B1 PLIN1 CCN2 LMX1B ACTA2 CD46 VHL CACNA1D G6PC PPARG MMP14 NPHP1 WRN APOA1 GP1BB KCNJ5 GPC3 ARHGAP31 RFC2 SMAD3 ND6 MAX SCNN1B ND6 CTLA4 PRTN3 SCNN1G RET PLIN1 USP8 C3 XYLT1 HLA-B XYLT2 FGA TRNC TRNF EPAS1 APOB BBS7 BBS2 BNC2 FOXE3 SDHC IQCB1 NOS3 BBS9 ABCC6 KIF1B COL4A5 H19 EDA2R CYP17A1 ELN PKHD1 HBB ENPP1 LIMK1 TBL2 LZTFL1 CPOX CEP164 USP8 CALR KIF1B SLC37A4 ZMPSTE24 TRNF SERPINA6 TMEM67 VHL JAK2 MDH2 ARMC5 SMARCAL1 FUZ ABCC6 TRNW POU3F4 SDHB NSMCE2 OFD1 MEF2A WT1 KLHL3 XPNPEP3 HIRA GNAS TP53 PDE3A CEP19 BANF1 SPRY2 INVS ADA2 BBS1 FBN1 NOD2 SDHC CLIP2 ERCC8 HSD11B2 NPHP3 TMEM127 HLA-DPB1 TNFRSF11B SDCCAG8 DLST MC4R CEP290 EGFR STAT1 TMEM127 COL3A1 YY1AP1 CAV1 COQ7 INVS ADA2 NOTCH1 TRNK BBS12 NFIX TRIP13 TRPC6 IDUA OFD1 LMX1B WDR35 ENPP1 BMPR2 CEP290 MFAP5 LMNA TRNK MKS1 POU6F2 PKD1 CC2D2A MAT2A MYH11 LDLR RET COL3A1 VHL CCDC28B SCN2B SDHB NOTCH2 ECE1 CDH23 IFT27 TRNV SMAD4 TRIM32 SDHAF2 GNAS MYLK ALMS1 ARL6 TSC2 AIP PRKAR1A WT1 ITGA8 TRIM28 ARVCF GTF2I LARS2 TRNW THPO COX3 CYP11B2 TMEM237 SLC37A4 CYP11B1 IFT172 COL5A1 SMAD6 TRAF3IP1 TMEM70 TRNH FH DNAJB11 NFU1 CFHR1 TBX1 BBS4 KCNJ5 COL4A3 AIP TRNS2 NR3C1 MLXIPL NPHP1 LMNA GUCY1A1 EDA SLC25A11 ACTA2 SCNN1A CFHR3 FMR1 LMNA TTC8 PRKG1 PRKACA TGFBR1 FIG4 ELP1 BAZ1B IL12B MAX IRF5 NPHP4 PHF21A ABCC6 RET WDPCP YY1AP1 CUL3 COL4A3 ADAMTSL4 BBS5 SLC52A3 OSGEP GANAB GNAS CYP21A2 TRNE SDHB ABCB6 VAC14 JAK2 RET SDHA PRKAR1A SDHD PCSK9 GDNF WT1 TET2 NR3C2 SMAD4 CLCN2 ABCG5 MPL C8ORF37 GTF2IRD1 VANGL1 TRNK THBD PRKAR1A
Primary Outcomes
Description: Prevalence of a previous treatment by angiotensin converting enzyme inhibitors in patients with and without confirmed Covid-19 pneumonia.
Measure: Prior treatment by ACEi Time: at admission to hospitalDescription: Prevalence of a previous treatment by angiotensin II type 1-receptor blockers in patients with and without confirmed Covid-19 pneumonia.
Measure: Prior treatment by ARB Time: at admission to hospitalSecondary Outcomes
Description: Association between COVID-19 infection status and other baseline characteristics and comorbidities (age, sex, history of hypertension, chronic heart disease, diabetes mellitus, COPD, asthma, obesity, allergies)
Measure: Baseline characteristics and comorbidities Time: at admission to hospitalDescription: Association between previous treatment by ACEi and ARBs and clinical course of COVID-19 (one-month mortality, hospitalization in intensive care unit, duration of hospital stay, early discharge to home)
Measure: Major Clinical Adverse Events Time: One month follow-up